Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Uterine Cervical Neoplasms 5Uterine Cervical Dysplasia 2Ovarian Neoplasms 2Atypical Squamous Cells of the Cervix 2Testicular Neoplasms 1Teratoma 1Squamous Intraepithelial Lesions 1Sarcoma 1Peritoneal Neoplasms 1Pelvic Organ Prolapse 1Ovarian Germ Cell Cancer 1Ototoxicity 1Osteosarcoma 1Neuroblastoma 1Medulloblastoma 1Liver Neoplasms 1Leiomyoma 1Hepatoblastoma 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Central Nervous System Neoplasms 1Carcinoma, Endometrioid 1Breast Neoplasms 1Brain Neoplasms 1Anus Neoplasms 1

Interventions

sodium thiosulfate 1Restraint, Physical 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ototoxicity × Restraint, Physical × Gynecologic × Clear all
NCT00716976 2023-11-09

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Children's Oncology Group

Phase 3 Completed
131 enrolled 18 charts 1 FDA
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Ovarian Germ Cell Cancer, Ototoxicity, Brain Neoplasms, Liver Neoplasms, Medulloblastoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡